Editas Medicine Stock Cash And Equivalents

EDIT Stock

USD 1.31 0.06 4.38%

Editas Medicine fundamentals help investors to digest information that contributes to Editas Medicine's financial success or failures. It also enables traders to predict the movement of Editas Stock. The fundamental analysis module provides a way to measure Editas Medicine's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Editas Medicine stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Editas Medicine Company Cash And Equivalents Analysis

Editas Medicine's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Cash

Bank Deposits

+

Liquidities

More About Cash And Equivalents | All Equity Analysis

Current Editas Medicine Cash And Equivalents

452.56 M

Most of Editas Medicine's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Editas Medicine is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Editas Cash And Equivalents Driver Correlations

Understanding the fundamental principles of building solid financial models for Editas Medicine is extremely important. It helps to project a fair market value of Editas Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Editas Medicine's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Editas Medicine's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Editas Medicine's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Property Plant Equipment	Net Tangible Assets	Current Deferred Revenue	Long Term Debt	Net Receivables	Deferred Long Term Liab	Short Long Term Debt	Short Term Debt	Common Stock	Short Term Investments	Capital Surpluse	Long Term Debt Total	Net Invested Capital	Net Working Capital	Long Term Investments	Capital Stock
Total Assets		0.95	-0.82	-0.72	0.86	0.73	0.99	0.6	0.93	0.62	0.83	0.3	0.91	0.74	0.84	0.66	0.96	0.86	-0.6	0.63	0.49	0.69	0.52
Total Stockholder Equity	0.95		-0.8	-0.66	0.81	0.47	0.9	0.49	0.93	0.57	0.64	0.22	0.8	0.54	0.8	0.63	0.93	0.83	-0.51	0.76	0.56	0.8	0.5
Net Debt	-0.82	-0.8		0.53	-0.71	-0.53	-0.84	-0.81	-0.8	-0.84	-0.66	-0.14	-0.74	-0.59	-0.53	-0.44	-0.76	-0.67	0.49	-0.41	-0.5	-0.36	-0.31
Retained Earnings	-0.72	-0.66	0.53		-0.79	-0.58	-0.68	-0.31	-0.82	-0.18	-0.65	-0.84	-0.85	-0.58	-0.82	-0.93	-0.7	-0.92	0.89	-0.19	0.12	-0.46	-0.92
Accounts Payable	0.86	0.81	-0.71	-0.79		0.65	0.82	0.56	0.83	0.54	0.77	0.45	0.84	0.69	0.87	0.73	0.79	0.87	-0.59	0.42	0.13	0.62	0.62
Total Liab	0.73	0.47	-0.53	-0.58	0.65		0.8	0.61	0.56	0.49	0.91	0.34	0.8	0.88	0.62	0.48	0.66	0.6	-0.56	0.12	0.15	0.19	0.38
Total Current Assets	0.99	0.9	-0.84	-0.68	0.82	0.8		0.69	0.89	0.66	0.86	0.26	0.92	0.77	0.78	0.6	0.95	0.81	-0.61	0.54	0.5	0.57	0.46
Property Plant Equipment	0.6	0.49	-0.81	-0.31	0.56	0.61	0.69		0.48	0.83	0.71	0.02	0.64	0.68	0.37	0.14	0.55	0.38	-0.37	0.01	0.23	-0.04	0.04
Net Tangible Assets	0.93	0.93	-0.8	-0.82	0.83	0.56	0.89	0.48		0.51	0.71	0.44	0.88	0.61	0.83	0.83	0.9	0.95	-0.66	0.6	0.35	0.7	0.72
Current Deferred Revenue	0.62	0.57	-0.84	-0.18	0.54	0.49	0.66	0.83	0.51		0.62	-0.12	0.49	0.6	0.32	0.09	0.52	0.35	-0.16	0.28	0.45	0.22	-0.05
Long Term Debt	0.83	0.64	-0.66	-0.65	0.77	0.91	0.86	0.71	0.71	0.62		0.34	0.83	0.98	0.8	0.57	0.69	0.72	-0.55	0.27	0.16	0.36	0.48
Net Receivables	0.3	0.22	-0.14	-0.84	0.45	0.34	0.26	0.02	0.44	-0.12	0.34		0.55	0.31	0.48	0.75	0.3	0.6	-0.85	-0.24	-0.52	0.11	0.84
Deferred Long Term Liab	0.91	0.8	-0.74	-0.85	0.84	0.8	0.92	0.64	0.88	0.49	0.83	0.55		0.74	0.79	0.73	0.92	0.87	-0.82	0.29	0.18	0.43	0.64
Short Long Term Debt	0.74	0.54	-0.59	-0.58	0.69	0.88	0.77	0.68	0.61	0.6	0.98	0.31	0.74		0.75	0.48	0.58	0.61	-0.49	0.2	0.12	0.28	0.41
Short Term Debt	0.84	0.8	-0.53	-0.82	0.87	0.62	0.78	0.37	0.83	0.32	0.8	0.48	0.79	0.75		0.8	0.74	0.88	-0.58	0.54	0.13	0.72	0.73
Common Stock	0.66	0.63	-0.44	-0.93	0.73	0.48	0.6	0.14	0.83	0.09	0.57	0.75	0.73	0.48	0.8		0.63	0.94	-0.72	0.32	-0.09	0.56	0.97
Short Term Investments	0.96	0.93	-0.76	-0.7	0.79	0.66	0.95	0.55	0.9	0.52	0.69	0.3	0.92	0.58	0.74	0.63		0.82	-0.65	0.58	0.5	0.63	0.48
Capital Surpluse	0.86	0.83	-0.67	-0.92	0.87	0.6	0.81	0.38	0.95	0.35	0.72	0.6	0.87	0.61	0.88	0.94	0.82		-0.71	0.47	0.13	0.66	0.86
Long Term Debt Total	-0.6	-0.51	0.49	0.89	-0.59	-0.56	-0.61	-0.37	-0.66	-0.16	-0.55	-0.85	-0.82	-0.49	-0.58	-0.72	-0.65	-0.71		0.07	0.13	-0.15	-0.74
Net Invested Capital	0.63	0.76	-0.41	-0.19	0.42	0.12	0.54	0.01	0.6	0.28	0.27	-0.24	0.29	0.2	0.54	0.32	0.58	0.47	0.07		0.76	0.9	0.18
Net Working Capital	0.49	0.56	-0.5	0.12	0.13	0.15	0.5	0.23	0.35	0.45	0.16	-0.52	0.18	0.12	0.13	-0.09	0.5	0.13	0.13	0.76		0.46	-0.26
Long Term Investments	0.69	0.8	-0.36	-0.46	0.62	0.19	0.57	-0.04	0.7	0.22	0.36	0.11	0.43	0.28	0.72	0.56	0.63	0.66	-0.15	0.9	0.46		0.45
Capital Stock	0.52	0.5	-0.31	-0.92	0.62	0.38	0.46	0.04	0.72	-0.05	0.48	0.84	0.64	0.41	0.73	0.97	0.48	0.86	-0.74	0.18	-0.26	0.45

Click cells to compare fundamentals

Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Competition

Predict Editas Medicine

Editas Cash And Cash Equivalents Changes

Cash And Cash Equivalents Changes

(53.01 Million)

At this time, Editas Medicine's Cash And Cash Equivalents Changes is comparatively stable compared to the past year.

In accordance with the recently published financial statements, Editas Medicine has 452.56 M in Cash And Equivalents. This is 44.87% lower than that of the Biotechnology sector and about the same as Health Care (which currently averages 447.12 M) industry. The cash and equivalents for all United States stocks is 83.25% higher than that of the company.

Editas Cash And Equivalents Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Editas Medicine's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Editas Medicine could also be used in its relative valuation, which is a method of valuing Editas Medicine by comparing valuation metrics of similar companies.

Editas Medicine is currently under evaluation in cash and equivalents category among its peers.

Editas Medicine Current Valuation Drivers

We derive many important indicators used in calculating different scores of Editas Medicine from analyzing Editas Medicine's financial statements. These drivers represent accounts that assess Editas Medicine's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Editas Medicine's important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	4.1B	1.8B	609.1M	769.5M	104.6M	99.3M
Enterprise Value	4.0B	1.6B	511.5M	682.4M	8.1M	7.7M

Editas Fundamentals

	Return On Equity	-0.98
	Return On Asset	-0.36
	Operating Margin	(1.12) %
	Current Valuation	(126.18 M)
	Shares Outstanding	82.98 M
	Shares Owned By Insiders	0.31 %
	Shares Owned By Institutions	66.15 %
	Number Of Shares Shorted	17.44 M
	Price To Earning	(7.02) X
	Price To Book	0.81 X
	Price To Sales	3.36 X
	Revenue	32.31 M
	Gross Profit	(166.93 M)
	EBITDA	(233.11 M)
	Net Income	(237.09 M)
	Cash And Equivalents	452.56 M
	Cash Per Share	6.59 X
	Total Debt	35.03 M
	Debt To Equity	0.04 %
	Current Ratio	12.67 X
	Book Value Per Share	1.62 X
	Cash Flow From Operations	(210.28 M)
	Short Ratio	2.31 X
	Earnings Per Share	(2.88) X
	Target Price	3.75
	Number Of Employees	246
	Beta	1.87
	Market Capitalization	108.7 M
	Total Asset	341.59 M
	Retained Earnings	(1.47 B)
	Working Capital	212.09 M
	Current Asset	144.99 M
	Current Liabilities	6.92 M
	Net Asset	341.59 M

About Editas Medicine Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Editas Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Editas Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Editas Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Editas Stock Analysis

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC